DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity
Journal for ImmunoTherapy of Cancer · 2026-01 · 14 (1) · e013142
DOI: 10.1136/jitc-2025-013142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.01.2026. Verfasst von Lijian Wang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Faculty of Health Sciences, University of Macau, Macau, People's Republic of China. Hauptthemen laut MEDLINE: Galectin 1, Dual-Specificity Phosphatases, CD8-Positive T-Lymphocytes, Mitogen-Activated Protein Kinase Phosphatases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Macau Multi-Year Research Grants, National Natural Science Foundation of China, The Science and Technology Development Fund, Macau S.A.R.
Abstract (Originalsprache)
Background
Insufficient infiltration of CD8 + T cells in the tumor microenvironment (TME) critically restricts antitumor immunity and cancer immunotherapy efficacy. The purpose of this study was to identify novel tumor cell-intrinsic regulators of T-cell infiltration and to elucidate their mechanisms of action.
Methods
We performed a genome-wide Sleeping Beauty transposon mutagenesis screen in murine breast cancer models. Protein–protein interactions were identified by mass spectrometry and validated by co-immunoprecipitation. Gene and protein expression levels were assessed by reverse transcription and quantitative PCR and western blotting. T-cell infiltration and function were evaluated using flow cytometry, immunohistochemistry (IHC), multiplex IHC, and by analyzing bulk and single-cell RNA sequencing data complemented by bioinformatic analysis. The specific dephosphorylation sites on LGALS1 were confirmed through phosphomimetic mutant experiments. T-cell infiltration was further validated using an in vitro T-cell transendothelial migration assay and in vivo mouse models.
Results
Our screening identified 39 candidate genes, with tumor cell-intrinsic dual-specificity phosphatase 22 (DUSP22) expression correlating with enhanced CD8 + T-cell accumulation and suppressed tumor progression. Overexpression of DUSP22 resulted in increased CD8 + T-cell infiltration and enhanced T-cell function. Mechanistically, DUSP22 binds to LGALS1 and dephosphorylates it at the Ser8 and Thr58 residues, leading to LGALS1 degradation and subsequent alleviation of LGALS1-mediated immunosuppression. In human breast cancer samples, LGALS1 expression was negatively correlated with both DUSP22 levels and CD8 + T-cell infiltration. Therapeutic targeting of the DUSP22-LGALS1 axis significantly enhanced CD8 + T-cell infiltration and synergized with anti-programmed cell death protein-1 therapy to boost antitumor responses.
Conclusions
Our findings unveil a novel phosphorylation-dependent DUSP22-LGALS1 axis that reprograms the immunosuppressive TME. This work thus proposes a promising therapeutic strategy to overcome immune checkpoint blockade resistance in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Faculty of Health Sciences, University of Macau, Macau, People's Republic of China.
- Centre for Precision Medicine Research and Training, Faculty of Health Sciences, University of Macau, Macau, People's Republic of China.
- Division of Hepatobiliary & Pancreatic, Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
- School of Pharmacy, Laboratory of Drug Discovery from Natural Resources and Industrialization, State Key Laboratory of Mechanism and Quality of Chines Medicine, Macau University of Science and Technology, Macau, People'…
- Zhuhai UM Science & Technology Research Institute, Zhuhai, People's Republic of China.
- MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau, People's Republic of China.
Förderung
- University of Macau Multi-Year Research Grants
- National Natural Science Foundation of China
- The Science and Technology Development Fund, Macau S.A.R
Zitieren
APA
Wang, L., Guo, Y., Dai, Y., Sun, W., Huang, X., Lei, H., Zhang, A., Chen, S., Li, Y., Pan, J., Hong, Y., Ma, L., Feng, Y., Shao, F., Zeng, J., Luo, P., Li, J., Chen, W., Zhou, N., …, & Miao, K. (2026). DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity. Journal for ImmunoTherapy of Cancer, 14(1), e013142. https://doi.org/10.1136/jitc-2025-013142
Vancouver
Wang L, Guo Y, Dai Y, Sun W, Huang X, Lei H, et al. DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity. Journal for ImmunoTherapy of Cancer. 2026;14(1):e013142. doi:10.1136/jitc-2025-013142
BibTeX
@article{Wang2026,
author = {Wang, Lijian and Guo, Yutong and Dai, Yujie and Sun, Wangsheng and Huang, Xiaoying and Lei, Haipeng and Zhang, Aiping and Chen, Shuwen and Li, Yiting and Pan, Jiani and Hong, Yangjian and Ma, Lingchuan and Feng, Yangyang and Shao, Fangyuan and Zeng, Jianming and Luo, Peng and Li, Junqi and Chen, Weiting and Zhou, Na and Li, Yang and Sun, Heng and Xu, Xiaoling and Deng, Chu-Xia and Miao, Kai},
title = {DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {1},
pages = {e013142},
doi = {10.1136/jitc-2025-013142}
}
EUVIMED